NCT03169816View on ClinicalTrials.gov

Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use Disorder

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 25, 2017

Primary Completion Date

August 30, 2019

Study Completion Date

August 30, 2019

Conditions
Opioid-use Disorder
Interventions
DRUG

Lorcaserin

Lorcaserin 10mg, twice daily

DRUG

Placebo

Matched placebo for lorcaserin condition dosed twice daily

Trial Locations (1)

10019

Substance Treatment and Research Service (STARS), Columbia University, New York

All Listed Sponsors
lead

New York State Psychiatric Institute

OTHER

NCT03169816 - Lorcaserin in Combination With XR-Naltrexone for Relapse Prevention in Opioid Use Disorder | Biotech Hunter | Biotech Hunter